Vitruvian Networks was co-founded by General Electric and the Mayo Clinic to solve key challenges in the commercialization and delivery of cell and gene therapies.
Through our solutions and expertise, our mission is to enable high quality personalized cell therapies for more patients.
Before co-founding Vitruvian Networks, Amy focused on healthcare new business creation for GE Ventures/ healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California’s $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.
Heidi M. Hagen
Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vitruvian Networks. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.
Razmik is a leading Business Software Executive. He is currently CTO and Co-founder for Vitruvian Networks. He was former CTO for EMC Documentum product family, leading Enterprise Content Management platform and solutions for Fortune 5000. Razmik was one of the original designers of Documentum platform. He was a founding member of Documentum team and helped grow it to become a leading force in Enterprise Content Management industry with an IPO in 1996 and eventual acquisition by EMC in 2003 for $1.7 Billion. Razmik is author of several patents and coauthor of several technical books. He is also investor and advisors to multiple high tech companies.
Malek Faham, M.D., Ph.D.
Dr. Malek Faham is Chief Scientific Officer and Co-founder of Vitruvian Networks. He was formerly co-founder and CSO of Sequenta Inc, where he led technology development, scientific direction, clinical validation, and operation from the initial vision in 2008 of the potential of immune receptor repertoire sequencing to the company’s acquisition in 2015 by Adaptive Biotechnologies. Previously, Dr. Faham co-founded Parallele Bioscience, Inc. in 2001 and served as its Director for Research until its acquisition by Affymetrix in 2005. He then served as VP of Oncology Technology Research at Affymetrix until 2008. He has published more than 50 peer-reviewed articles and has over 100 issued and pending patents. Dr. Faham received his MD, Ph.D. in biochemistry and human genetics and Psychiatry residency training from University of California San Francisco, and had his post doctoral training with Professor Ronald W. Davis in the Stanford Genome Technology Center.
Board of Directors
Emily is a partner at DFJ and has spent more than a decade working with early stage companies. Emily's primary areas of interest include consumer and mobile technology, healthcare technologies and marketplaces. Her investments include BetterUp, Elation Health, Livongo, Redfin, Shift, and Wellframe. Emily started her career at DFJ and spent eight years at the firm where she sourced and became actively involved in consumer and enterprise investments including Meebo (acquired by Google), Flux (acquired by MTVNetworks), Kudo (acquired by Google), Redfin, ShareThis, and RichRelevance. Recently, she was an advisor to Pulse Networks (acquired by LinkedIn), HealthTap, and PoshMark. She holds a BA with honors and distinction in political philosophy and an MBA, both from Stanford University.
Nigel has worked in a variety of executive positions in GE Healthcare Life Sciences, most recently as VP of the BioProcess business from 2008-2016 and currently works as an Advisor to the CEO. Previously Nigel had been VP for Chemistry Technology at AstraZeneca. Prior to entering industry he had spent 16 years in academic research in medicine and molecular biology for the UK Medical Research Council and in Germany at EMBL, Heidelberg. Nigel received his first degree in Natural Sciences from the University of Cambridge, U.K in 1981 and his Ph.D. in Biochemistry from the University of Kent, U.K. in 1985.
Risa leads the GE Ventures, New Business Creation team. The team has started companies in healthcare and other industries including: Evidation Health, Vitruvian Networks, Current powered by GE, and Menlo Microsystems. Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT). Risa holds a degree in genetics and development with distinction from the University of Illinois, a Ph.D. in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.
Rowan is Head of J&J Innovation, CA. She leads the team responsible for identifying, investing and partnering with the entrepreneurial ecosystem across the J&J Pharmaceutical, Medical Device and Consumer sectors. Prior to J&J Rowan served as Head of Healthcare Investing at GE Ventures where she was a member of the Vitruvian founding team. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. Previously she spent 11 years as a Partner at Mohr Davidow Ventures, was a very early employee at Rosetta Inpharmatics, and Incyte Genomics. Rowan holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco.